Diabetes

Latest News


While the pharmaceutical industry has always justified the billions spent on developing a candidate drug molecule, the process has definitely seen some important changes. This article evaluates whether these revolutionary changes have influenced drug development for the better.

Budget cuts mean county health clinics will be unable to fill hundreds of jobs, leaving smaller staffs to serve low-income people in state that declined to expand Medicaid despite pleas from its hospitals and business leaders.

The 2015 Dietary Guidelines Advisory Committee met for more than a year to review scientific evidence and discuss "patterns" of food consumption, and those discussions are reflected in the report. After a 45-day comment period and public hearing, the US Secretaries of Agriculture and Health and Human Services will issue the final Dietary Guidelines for Americans, the nation's official nutrition policy.

A one-minute look at managed care news during the week of February 9, 2015, including an announcement of a new Affordable Care Initiative and a potential change to recommended dietary guidelines.

The situation with hepatitis C drug costs is setting an interesting precedent for the rest of healthcare and one that needs to be watched closely, according to Keith Hoffman, PhD.

An editorial accompanying the meta-analysis discussed the challenges physicians face when evaluating individual patient needs against guidelines. In the United States, the movement toward reimbursement based on population health measures has raised questions about whether it makes sense for patients to be given multiple medications to achieve small improvements toward targets. Results must be weighed against increased side affects or large out-of-pocket expenditures.

After nearly 6 years overseeing public health initiatives, Margaret Hamburg, MD, commissioner of the FDA will be stepping down, according to various sources.

In his blog post on FDAVoice, Peter Lurie MD, MPH, associate FDA commissioner for public health strategy and analysis, announced the introduction of a draft form and a draft guideline that can be used by a physician to request access to an experimental drug or biological product that is still under development.